ArticleJCI insight2020
Platelet factor 4 is a biomarker for lymphatic-promoted disorders.
Article in JCI insight, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06549738 (Effects of Intermittent Pneumatic Compression Therapy on Tissue Volume, Pain, and Quality of Life in Women Living With Lipedema), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Intermittent Pneumatic Compression Therapy on Tissue Volume, Pain, and Quality of Life in Women Living With Lipedema
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Lipedema: Progress, Challenges, and the Road Ahead.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2025Pooled it
- Article
- Cooperative ETS transcription factors are required for lymphatic endothelial cell integrity and resilience.The Journal of clinical investigation · 2026Article
- Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema.Breast cancer research : BCR · 2026Article
- From stasis to systematics: deciphering the pathophysiology of secondary lymphedema through omics.Frontiers in immunology · 2026Review
- Profibrotic macrophage-derived CXCL4 promotes pericyte-to-myofibroblast transition after spinal cord injury.Journal of orthopaedic translation · 2026Article
- The role of extracellular vesicles in the context of (inter-)cellular communication contributing to adipose tissue dysfunction in lipedema.Frontiers in cell and developmental biology · 2026Review
- Lipedema and Hypermobility Spectrum Disorders Sharing Pathophysiology: A Cross-Sectional Observational Study.Journal of clinical medicine · 2025Article
- Exploring uric acid as a biomarker in lipedema and lymphedema: A metabolomics study with prospective validation.Obesity medicine · 2025Article
- Metabolic Alterations in Women with Lipedema Compared to Women with Lifestyle-Induced Overweight/Obesity.Biomedicines · 2025Article
- Lipedema: A Disease Triggered by M2 Polarized Macrophages?Biomedicines · 2025Review
- Lipedema and adipose tissue: current understanding, controversies, and future directions.Frontiers in cell and developmental biology · 2025Review
- Brazilian Consensus Statement on Lipedema using the Delphi methodology.Jornal vascular brasileiro · 2025Article
- Identification of Specific microRNAs in Adipose Tissue Affected by Lipedema.Current issues in molecular biology · 2024Article
- Article
- Proposed Framework for Research Case Definitions of Lipedema.Lymphatic research and biology · 2024Review
- Ketogenic Diet: A Nutritional Therapeutic Tool for Lipedema?Current obesity reports · 2023Review
- A narrative review: CXC chemokines influence immune surveillance in obesity and obesity-related diseases: Type 2 diabetes and nonalcoholic fatty liver disease.Reviews in endocrine & metabolic disorders · 2023Review
- Lipedema Research-Quo Vadis?Journal of personalized medicine · 2022Review
- Lipedema: Insights into Morphology, Pathophysiology, and Challenges.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
Abstract
Genetic or acquired defects of the lymphatic vasculature often result in disfiguring, disabling, and, occasionally, life-threatening clinical consequences. Advanced forms of lymphedema are readily diagnosed clinically, but more subtle presentations often require invasive imaging or other technologies for a conclusive diagnosis. On the other hand, lipedema, a chronic lymphatic microvascular disease with pathological accumulation of subcutaneous adipose tissue, is often misdiagnosed as obesity or lymphedema; currently there are no biomarkers or imaging criteria available for a conclusive diagnosis. Recent evidence suggests that otherwise-asymptomatic defective lymphatic vasculature likely contributes to an array of other pathologies, including obesity, inflammatory bowel disease, and neurological disorders. Accordingly, identification of biomarkers of lymphatic malfunction will provide a valuable resource for the diagnosis and clinical differentiation of lymphedema, lipedema, obesity, and other potential lymphatic pathologies. In this paper, we profiled and compared blood plasma exosomes isolated from mouse models and from human subjects with and without symptomatic lymphatic pathologies. We identified platelet factor 4 (PF4/CXCL4) as a biomarker that could be used to diagnose lymphatic vasculature dysfunction. Furthermore, we determined that PF4 levels in circulating blood plasma exosomes were also elevated in patients with lipedema, supporting current claims arguing that at least some of the underlying attributes of this disease are also the consequence of lymphatic defects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.